Overview

SB-681323 In Subjects With Rheumatoid Arthritis

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline